Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pecoits-Filho, R.
Right arrow Articles by Stenvinkel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pecoits-Filho, R.
Right arrow Articles by Stenvinkel, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 1042-1045
© 2003 European Renal Association-European Dialysis and Transplant Association

Editorial Comment

Update on interleukin-6 and its role in chronic renal failure

Roberto Pecoits-Filho, Bengt Lindholm, Jonas Axelsson and Peter Stenvinkel

Division of Nephrology and Baxter Novum, Department of Clinical Science, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden

Keywords: atherosclerosis; chronic renal failure; inflammation; interleukin-6; malnutrition; mortality

The first 150 words of the full text of this article appear below.

Introduction

Although a number of pro-inflammatory [such as tumour necrosis factor (TNF)-{alpha} and interleukin (IL)-1] and anti-inflammatory (such as IL-10) cytokines orchestrate the inflammatory response, available data suggest that IL-6 and its soluble receptor (sIL-6R) are central regulators of the inflammatory process [1]. The IL-6 system promotes inflammatory events through the activation and proliferation of lymphocytes, differentiation of B cells, leukocyte recruitment and the induction of the acute-phase protein response in the liver [2]. Chronic inflammation is increasingly recognized as an important issue due to its role in various pathological states, such as cardiovascular disease, obesity, diabetes, cancer and malnutrition [2]. Significant epidemiological information has recently linked plasma IL-6 to cardiovascular morbidity and mortality in non-renal patient groups [3]. Also, in end-stage renal disease (ESRD) patients an elevated IL-6 level is a strong predictor of poor outcome [4].

IL-6 is a . . . [Full Text of this Article]

Causes of elevated IL-6 in ESRD

Clinical consequences of elevated IL-6 levels

Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 pdiHome page
R. Pecoits-Filho
APPLYING TRANSLATIONAL RESEARCH IN UNDERSTANDING COMPLICATIONS AND DEFINING TARGETS FOR INTERVENTION: INFLAMMATION IN PD AS A MODEL
Perit. Dial. Int., March 1, 2009; 29(2): 135 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
B. Memoli, G. Grandaliano, M. Soccio, L. Postiglione, B. Guida, V. Bisesti, P. Esposito, A. Procino, D. Marrone, A. Michael, et al.
In Vivo Modulation of Soluble "Antagonistic" IL-6 Receptor Synthesis and Release in ESRD
J. Am. Soc. Nephrol., April 1, 2005; 16(4): 1099 - 1107.
[Abstract] [Full Text] [PDF]